… drugs (anastrozole, letrozole and exemestane) have been … of patients without any differences
between the two AIs used in … A phase II trial conducted by the Hellenic Group of Oncology (…

… In this report, we present the results of a phase II neoadjuvant trial, performed at the …
comparison between the two non-steroidal AIs and direct competitors, anastrozole and letrozole, …

… Baseline tumor Ki67 index showed no statistical differences between NET and NAC groups
(P … Therefore, in our future randomized controlled phase II or III trial with larger sample size, a …

… ) Z1031 was a randomized phase 2 neoadjuvant clinical trial … either exemestane (2.5 mg
daily), anastrozole (1 mg daily), or … The ALTERNATE (Alternate Approaches for Clinical Stage II …

… Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or >66%)/ERBB2-negative
breast cancer were included. All analyses were based on data frozen on March 2…

… ), aromatase inhibitors (eg, letrozole, anastrozole, and exemestane), and the first-generation …
versus anastrozole corresponded to an effect size of 0·3 (ie, the difference between two …

… A randomized trial of exemestane after two to three years of … , previous adjuvant or neoadjuvant
chemotherapy, and body-… 10 years showed no differences between the two groups. 5-…

… , and letrozole and anastrozole are superior to exemestane. … different durations of
neoadjuvant treatment with letrozole in … or partial response to neoadjuvant letrozole as well as to …

… a phase II trial … difference between the once-daily and 3-times-weekly arms. The PgR
reduction was identified in this presurgical study and in different neoadjuvant studies of exemestane…

… Differences among treatment groups were evaluated using Fisher’s … to neoadjuvant therapy
in invasive cancer. We found that the majority of MRI changes were seen early in letrozole …